This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.
Illumina (ILMN) Launches Initiative on Pathogen Sequencing
by Zacks Equity Research
Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.
Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.
Prestige Consumer's (PBH) Brand Building, Innovation Aid Growth
by Zacks Equity Research
Prestige Consumer's (PBH) long-term brand-building efforts, efficient marketing, channel development and innovation help the company to continually hold a leading market share position.
QIAGEN (QGEN) Launches QIAcuity Kits and Software Update
by Zacks Equity Research
QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.
Here's Why You Should Retain Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.
Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure
by Zacks Equity Research
Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Charles River (CRL) to Advance AI Drug Discovery With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.
Henry Schein (HSIC) Q3 Revenues Miss, 2023 Guidance Cut
by Zacks Equity Research
Henry Schein's (HSIC) third-quarter 2023 performance demonstrates remarkable sales growth in the Technology and Value-Added Service businesses.
Humana's (HUM) CenterWell Unit Plans Expansion in Indiana
by Zacks Equity Research
Humana's (HUM) CenterWell brand will open four senior-focused primary care centers across Indianapolis in order to address the unique needs of the area's senior population.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) strength in Health Care Benefits business arm and stable solvency position.
Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service
by Zacks Equity Research
Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.
IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis
by Zacks Equity Research
IDEXX (IDXX) expands the SNAP franchise with a comprehensive solution for detecting canine leishmaniosis.
Hologic's (HOLX) Q4 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Solid year-over-year growth in the Breast Health segment drives Hologic's (HOLX) Q4 performance.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
National Vision's (EYE) higher SG&A expenses in the third quarter reflect increases in performance-based incentives and stock-based compensations.
Illumina (ILMN) Q3 Earnings Surpass Estimates, '23 View Cut
by Zacks Equity Research
Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.
BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.
Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.
Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the third quarter.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business and momentum in ProCyte One expansion.
Phibro (PAHC) Q1 Earnings and Revenues Miss, Margins Down
by Zacks Equity Research
Phibro's (PAHC) fiscal 2024 first-quarter performance reflects reduced sales in Mineral Nutrition and Performance Products.
Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y
by Zacks Equity Research
Despite higher international business-to-business sales and rental revenues, Inogen's (INGN) overall third-quarter results reflect soft performances.
Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.